Send to

Choose Destination
Oncoimmunology. 2013 Jun 1;2(6):e24452. Epub 2013 May 14.

Use of a KIT-specific monoclonal antibody to bypass imatinib resistance in gastrointestinal stromal tumors.

Author information

Department of Pathology; Stanford University School of Medicine; Stanford, CA USA ; Department of Genetics; Stanford University School of Medicine; Stanford, CA USA.


Acquired resistance to imatinib is a significant problem for the clinical management of gastrointestinal stromal tumor (GIST) patients, and second-line small molecules have shown limited efficacy in this setting. We have recently demonstrated that a monoclonal antibody targeting KIT could potentially bypass imatinib resistance in preclinical models of GIST.


CD117; KIT; gastrointestinal stromal tumor; imatinib; monoclonal antibody-based cancer therapy; receptor tyrosine kinase

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center